Advancing Next-Generation Biopreservation for Cell Therapy
CaseBioscience® Launches CaseCryo® CTG DMSO and CaseStor® HSS at ATW 2026, Advancing Next-Generation Biopreservation for Cell Therapy
Introducing clinical-grade cryopreservation and hypothermic storage solutions designed for consistency, quality, and performance across cell therapy workflows
February 2026 – CaseBioscience® announces the launch of CaseCryo® CTG DMSO, a next-generation cryopreservation solution developed for clinical cell therapy applications, at Advanced Therapies Week (ATW) 2026. CaseStor® HSS Hypothermic Storage Solution, designed for the hypothermic storage of cells and tissues for clinical use, will also be introduced at the meeting, expanding the company’s portfolio of biopreservation solutions for sensitive clinical workflows.
CaseCryo® CTG DMSO is produced under ISO 13485:2016–certified quality systems at CaseBioscience’s FDA-registered facility and applies regulatory and quality principles drawn from highly regulated assisted reproductive technology (ART) workflows. A Drug Master File (DMF) is currently being filed to support clinical development and manufacturing programs. CaseCryo® CTG DMSO is engineered with a systems-level view of cryopreservation as an end-to-end process, supporting sustained cell survival, functional performance, and manufacturing consistency beyond immediate post-thaw viability.
CaseStor® HSS provides a clinically oriented solution for hypothermic storage of cells and tissues, supporting a wide range of applications. A DMF for CaseStor® HSS is also in preparation to facilitate clinical translation and regulatory alignment. Together, CaseCryo® CTG DMSO and CaseStor® HSS reflect CaseBioscience’s commitment to delivering robust biopreservation solutions for both cryogenic and hypothermic workflows in clinical cell therapy.
“Cryopreservation and hypothermic storage are critical to enabling cell and tissue therapies,” said Kevin Flynn, PhD, Chief Scientific Officer at CaseBioscience®. “With CaseCryo® CTG DMSO and CaseStor® HSS, we’re providing solutions built for clinical applications that prioritize long-term cell performance, quality, and regulatory rigor.”
The launch of CaseCryo® CTG DMSO and CaseStor® HSS expands CaseBioscience’s biopreservation portfolio, which also includes CaseCryo® DMSO, CaseBase® Washing Medium, and CaseBase® Dissociation Medium for cell therapy research. CaseCryo® CTG Non-DMSO is also in development, reflecting ongoing efforts to advance alternative cryoprotectant strategies for clinical applications.
CaseBioscience’s research was recently highlighted at the ISSCR PSC-Derived Therapies Symposium, where the company presented a poster titled “An AI-assisted literature screening approach identifies potential DMSO-free cryoprotectants for optimal preservation of human Pluripotent- and Neural- Stem Cells.” This work underscores the company’s ongoing commitment to next-generation biopreservation solutions that support emerging cell therapy modalities.
Attendees of ATW 2026 are invited to visit the CaseBioscience team at booth #313 to learn more about CaseCryo® CTG DMSO, CaseStor® HSS Hypothermic Storage Solution, and the company’s vision for biopreservation built for clinical cell therapy.
About CaseBioscience®
CaseBioscience® is a research-driven biotechnology company advancing cell therapy and reproductive medicine through next-generation biopreservation and embryo culture solutions. Rooted in stem cell science and guided by ART-derived regulatory and quality principles, the company focuses on precision, consistency, and outcomes. Recent launches include FDA-cleared CaseBio Culture and CaseBio Handling solutions for embryo culture, with additional submissions in progress, reflecting CaseBioscience’s dedication to providing safe, effective, and high-quality solutions for clinical and research applications.